Remetinostat

CAS No. 946150-57-8

Remetinostat( SHP-141 )

Catalog No. M24995 CAS No. 946150-57-8

Remetinostat is a hydroxamic acid-based inhibitor of histone deacetylase enzymes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 32 In Stock
5MG 29 In Stock
10MG 46 In Stock
25MG 91 In Stock
50MG 145 In Stock
100MG 233 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Remetinostat
  • Note
    Research use only, not for human use.
  • Brief Description
    Remetinostat is a hydroxamic acid-based inhibitor of histone deacetylase enzymes.
  • Description
    Remetinostat is a hydroxamic acid-based inhibitor of histone deacetylase enzymes. It is under development for the treatment of cutaneous T-cell lymphoma.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    SHP-141
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    946150-57-8
  • Formula Weight
    323.34
  • Molecular Formula
    C16H21NO6
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:150 mg/mL (463.91 mM; Need ultrasonic)
  • SMILES
    COC(=O)C1=CC=C(C=C1)OC(=O)CCCCCCC(=O)NO
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yijun Deng, et al. Process Development of the Soft Histone Deacetylate Enzyme Inhibitor SHP-141: Acylation of Methyl Paraben and Suberyl Hydroxamic Acid Formation. Org. Process Res. Dev. 2016, 20, 10, 1812-1820.
molnova catalog
related products
  • SALL4 peptide FFW

    SALL4 peptide FFW (RRKFAKFQWI, FFW peptide) is a potent therapeutic SALL4 peptide antagonist of SALL4-NURD.

  • Resminostat hydrochl...

    A potent inhibitor of HDAC1/3/6 with IC50s of 43-72 nM; induces hyperacetylation of histone H4 and apoptosis in MM cell lines (IC50=2.5-3 uM).

  • Quisinostat

    Quisinostat (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11.